Items tagged with Vaccines
Long-term follow-up of participants in clinical trials of a generic vaccine to reverse advanced type 1 diabetes finds significant clinical benefits, including restoration of near-normal blood sugar levels. Three years after receiving two administrations of the bacillus Calmette-Guérin (BCG) vaccine four weeks apart, all members of a group of adults with longstanding type 1 diabetes showed an improvement in HbA1c to near normal levels – improvement that persisted for the following five years. The study from a Massachusetts General Hospital (MGH) research team – published in npj Vaccines – also reports that the effects of BCG vaccine on blood sugar control appear to depend on a totally novel metabolic mechanism that increases cellular consumption of glucose.
New England Journal of Medicine publishes final results from innovative Phase 2 study showing vaccines can reduce rate of sustained TB infections in adolescents at high risk (post)
Trial offers hope for new revaccination strategies with Bacille Calmette-Guerin (BCG) against TB, the world’s leading infectious disease killer.
Many of the vaccines critically needed to fight some of the world’s most prevalent infectious diseases are not likely to be developed, a new analysis of current candidates in the research and development pipeline has found.
In the effort to eradicate tuberculosis as one of the world’s most deadly diseases, novel TB vaccines will be an important part of the solution. There is a pipeline of new TB vaccines that requires a global and comprehensive coordination of efforts with defined stages of development and criteria for progression of individual vaccine candidates.
GSK candidate vaccine helps prevent active pulmonary TB in HIV negative adults in phase II study (post)
Publication of primary results in the New England Journal of Medicine shows positive impact of innovative vaccine technology in clinical trial conducted in tuberculosis endemic regions.
Data from two Phase II clinical trials conducted by Aeras and partners indicate promise for future of TB vaccine development.
THE HAGUE, Netherlands, October 25, 2018 – When the Ebola outbreak hit West Africa in 2014 and took more than 11,000 lives in two years, public and private organizations mobilized the development of a vaccine in a year and a half. That vaccine now is being used to control the current outbreak in the Democratic Republic of Congo.
Money is just the obvious obstacle. A few diseases, like H.I.V., so far have outwitted both the immune system and scientists.
Immunitor signs agreement to initiate steps toward clinical development of oral TB vaccine in China (post)
HONG KONG, HONG KONG, November 27, 2018 -- Immunitor China Ltd. (Hong Kong) announces signing a service agreement with Kun Tuo Medical Research and Development (Beijing) Co., Ltd. - China-based subsidiary of global contract research organization (CRO) – IQVIA, formerly Quintiles. The signed agreement aims to provide registration regulatory consultation before starting clinical trial and ultimately the commercialization of the first-in-class therapeutic vaccine designed to treat tuberculosis. This landmark document is a preliminary step which will lead to filing a clinical trial application with the National Medical Products Administration (NMPA, formerly CFDA) – the China government regulatory organization, which approves and monitors clinical trials in mainland China and ultimately grants marketing authorization.
Doctors, public health officials, and governments are facing what is now the second largest Ebola outbreak in history. The death toll from this latest outbreak in the northeastern region of the Democratic Republic of Congo (DRC) already totals 245. And experts warn it could potentially spread within the DRC, as well as to neighboring countries.
Page 11 of 14 · Total posts: 0←First 10 11 12 Last→